New therapeutic approaches to subarachnoid hemorrhage

Expert Opinion on Investigational Drugs

Volumn 21, Issue 6, 2012, Pages 845-859

  Barry, Christine ^b   Turner, Renée J ^a   Corrigan, Frances ^a   Vink, Robert ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Cerebral autoregulation; Cerebral edema; Cerebral perfusion; Intracranial pressure; Vasospasm

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CARBAMAZEPINE; CLAZOSENTAN; COLLAGENASE; DEXAMETHASONE; DOBUTAMINE; ENDOTHELIN 1; ERYTHROPOIETIN; FASUDIL; GELATINASE B; HEMOGLOBIN; INSULIN; MAGNESIUM; MAGNESIUM SULFATE; METHYLPREDNISOLONE; NICARDIPINE; NIMODIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEROTONIN; SILDENAFIL; SIMVASTATIN; STRESS HORMONE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

ANEMIA; AUTOREGULATION; BLEEDING DISORDER; BLOOD BRAIN BARRIER; BRAIN CIRCULATION; BRAIN EDEMA; BRAIN INFARCTION; BRAIN MICROCIRCULATION; BRAIN PERFUSION; BRAIN VASOSPASM; CELL DAMAGE; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DIFFUSION WEIGHTED IMAGING; DNA CLEAVAGE; DRUG MEGADOSE; DRUG OVERDOSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEMODILUTION; HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; INFLAMMATION; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; LUNG EDEMA; META ANALYSIS; MORBIDITY; MORTALITY; NATRIURESIS; NONHUMAN; OXIDATIVE STRESS; PERFUSION PRESSURE; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SODIUM TRANSPORT; SPREADING CORTICAL DEPRESSION; SUBARACHNOID HEMORRHAGE;

ANIMALS; BRAIN INJURIES; BRAIN ISCHEMIA; DRUG DELIVERY SYSTEMS; HUMANS; INTRACRANIAL HYPERTENSION; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; SECONDARY PREVENTION; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; VASOSPASM, INTRACRANIAL;

EID: 84861031503     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.683113     Document Type: Review

References (156)

1. Ingall T, Asplund K, Mahonen M, et al. A multinational comparison of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. Stroke 2000;31:1054-61 (Pubitemid 30253525)
2. Dimopoulou I, Kouyialis AT, Tzanella M, et al. High incidence of neuroendocrine dysfunction in long-term survivors of aneurysmal subarachnoid hemorrhage. Stroke 2004;35:2884-9 (Pubitemid 39565189)
3. Miyazaki T, Ohta F, Moritake K, et al. The key to improving prognosis for aneurysmal subarachnoid hemorrhage remains in the pre-hospitalization period. Surg Neurol 2006;65:360-5 (Pubitemid 43384078)
4. Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. Stroke 2001;32:1176-80 (Pubitemid 32825805)
5. Rabinstein AA, Weigand S, Atkinson JL, et al. Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2005;36:992-7 (Pubitemid 40629290)
6. Soehle M, Chatfield DA, Czosnyka M, et al. Predictive value of initial clinical status, intracranial pressure and transcranial Doppler pulsatility after subarachnoid haemorrhage. Acta Neurochir (Wien) 2007;149:575-83 (Pubitemid 46835141)
7. Rasulo FA, Girardini A, Lavinio A, et al. Are optimal cerebral perfusion pressure and cerebrovascular autoregulation related to long-term outcome in patients with aneurysmal subarachnoid hemorrhage? J Neurosurg Anesthesiol 2011;24:3-8
8. Bederson JB, Levy AL, Ding WH, et al. Acute vasoconstriction after subarachnoid hemorrhage. Neurosurgery 1998;42:352-60
9. Schubert GA, Seiz M, Hegewald AA, et al. Hypoperfusion in the acute phase of subarachnoid hemorrhage. Acta Neurochir Suppl 2011;110:35-8
10. Heros RC, Zervas NT, Varsos V. Cerebral vasospasm after subarachnoid hemorrhage: an update. Ann Neurol 1983;14:599-608 (Pubitemid 14211605)
11. Vergouwen MD, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and-independent effects. Stroke 2011;42:924-9
12. Czosnyka M, Steiner L, Balestreri M, et al. Concept of "true ICP" in monitoring and prognostication in head trauma. Acta Neurochir Suppl 2005;95:341-4
13. Scholler K, Trinkl A, Klopotowski M, et al. Characterization of microvascular basal lamina damage and blood-brain barrier dysfunction following subarachnoid hemorrhage in rats. Brain Res 2007;1142:237-46 (Pubitemid 46413192)
14. Sehba FA, Friedrich V Jr, Makonnen G, et al. Acute cerebral vascular injury after subarachnoid hemorrhage and its prevention by administration of a nitric oxide donor. J Neurosurg 2007;106:321-9 (Pubitemid 46203162)
15. Helbok R, Ko SB, Schmidt JM, et al. Global cerebral edema and brain metabolism after subarachnoid hemorrhage. Stroke 2011;42:1534-9
16. Sehba FA, Mostafa G, Friedrich V Jr, et al. Acute microvascular platelet aggregation after subarachnoid hemorrhage. J Neurosurg 2005;102:1094-100 (Pubitemid 43193979)
17. Dreier JP, Woitzik J, Fabricius M, et al. Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. Brain 2006;129:3224-37 (Pubitemid 44871438)
18. Tomycz L, Shekhawat N, Forbes J, et al. The spectrum of management practices in nontraumatic subarachnoid hemorrhage: a survey of high-volume centers in the United States. Surg Neurol Int 2011;2:90
19. Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009;40:994-1025 .
20. Guo LM, Zhou HY, Xu JW, et al. Risk factors related to aneurysmal rebleeding. World Neurosurg 2011;76:292-8
21. Dunn LT. Raised intracranial pressure. J Neurol Neurosurg Psychiatry 2007;73:i23-i7
22. Barry CM, Helps SC, den Heuvel C, et al. Characterizing the role of the neuropeptide substance P in experimental subarachnoid hemorrhage. Brain Res 2011;1389:143-51
23. Doczi T. The pathogenetic and prognostic significance of blood-brain barrier damage at the acute stage of aneurysmal subarachnoid haemorrhage. Clinical and experimental studies. Acta Neurochir (Wien) 1985;77:110-32 (Pubitemid 16214427)
24. Park S, Yamaguchi M, Zhou C, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke 2004;35:2412-17 (Pubitemid 39311273)
25. Chovanes GI, Richards RM. The predominance of metabolic regulation of cerebral blood flow and the lack of "Classic" autoregulation curves in the viable brain. Surg Neurol Int 2012;3:12
26. Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with statins on cerebral autoregulation in patients after aneurysmal subarachnoid hemorrhage. Neurosurg Focus 2006;21:E10
27. Treggiari MM. Hemodynamic management of subarachnoid hemorrhage. Neurocrit Care 2011;15:329-35
28. Rabinstein AA, Bruder N. Management of hyponatremia and volume contraction. Neurocrit Care 2011;15:354-60
29. Rosner MJ, Becker DP. Origin and evolution of plateau waves. Experimental observations and a theoretical model. J Neurosurg 1984;60:312-24 (Pubitemid 14177708)
30. Kavanagh RJ, Kam PC. Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth 2001;86:110-19 (Pubitemid 32015592)
31. Edvinsson L. Neuropeptide Y and the cerebral circulatin. In: Zukowska ZaF GZ, editor. NPY Family of Peptides in Neurobiology, Cardiovascular and Metabolic Disorders: from Genes to Therapeutics. Birkhauser Verlag; Switzerland: 2006. p. 105-12
32. Weidauer S, Lanfermann H, Raabe A, et al. Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke 2007;38:1831-6 (Pubitemid 46847255)
33. Alaraj A, Wallace A, Mander N, et al. Outcome following symptomatic cerebral vasospasm on presentation in aneurysmal subarachnoid hemorrhage: coiling vs. clipping. World Neurosurg 2010;74:138-42
34. Ansar S, Vikman P, Nielsen M, et al. Cerebrovascular ETB, 5-HT1B, and AT1 receptor upregulation correlates with reduction in regional CBF after subarachnoid hemorrhage. Am J Physiol Heart Circ Physiol 2007;293:H3750-8 (Pubitemid 350230923)
35. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980;6:1-9 (Pubitemid 10159923)
36. Sercombe R, Dinh YR, Gomis P. Cerebrovascular inflammation following subarachnoid hemorrhage. Jpn J Pharmacol 2002;88:227-49 (Pubitemid 34302973)
37. Wickman G, Lan C, Vollrath B. Functional roles of the rho/rho kinase pathway and protein kinase C in the regulation of cerebrovascular constriction mediated by hemoglobin: relevance to subarachnoid hemorrhage and vasospasm. Circ Res 2003;92:809-16 (Pubitemid 36457647)
38. Sobey CG, Quan L. Impaired cerebral vasodilator responses to NO and PDE V inhibition after subarachnoid hemorrhage. Am J Physiol 1999;277:H1718-24
39. Uhl E, Lehmberg J, Steiger HJ, et al. Intraoperative detection of early microvasospasm in patients with subarachnoid hemorrhage by using orthogonal polarization spectral imaging. Neurosurgery 2003;52:1307-15
40. Ellis EM. Reactive carbonyls and oxidative stress: potential for therapeutic intervention. Pharmacol Ther 2007;115:13-24 (Pubitemid 46990552)
41. Alexandrova ML, Bochev PG. Oxidative stress during the chronic phase after stroke. Free Radic Biol Med 2005;39:297-316 (Pubitemid 40910187)
42. Werner C, Engelhard K. Pathophysiology of traumatic brain injury. Br J Anaesth 2007;99:4-9 (Pubitemid 47072553)
43. Gaetani P, Marzatico F, Rodriguez Y, Baena R, et al. Arachidonic acid metabolism and pathophysiologic aspects of subarachnoid hemorrhage in rats. Stroke 1990;21:328-32 (Pubitemid 20067940)
44. Lin CL, Hsu YT, Lin TK, et al. Increased levels of F2-isoprostanes following aneurysmal subarachnoid hemorrhage in humans. Free Radic Biol Med 2006;40:1466-73
45. Pyne-Geithman GJ, Caudell DN, et al. Glutathione peroxidase and subarachnoid hemorrhage: implications for the role of oxidative stress in cerebral vasospasm. Neurol Res 2009;31:195-9
46. Marzatico F, Gaetani P, Rodriguez Y, Baena R, et al. Bioenergetics of different brain areas after experimental subarachnoid hemorrhage in rats. Stroke 1988;19:378-84
47. Marzatico F, Gaetani P, Cafe C, et al. Antioxidant enzymatic activities after experimental subarachnoid hemorrhage in rats. Acta Neurol Scand 1993;87:62-6 (Pubitemid 23023671)
48. Gaetani P, Pasqualin A, Rodriguez Y, Baena R, et al. Oxidative stress in the human brain after subarachnoid hemorrhage. J Neurosurg 1998;89:748-54 (Pubitemid 28485534)
49. Sehba FA, Pluta RM, Zhang JH. Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury. Mol Neurobiol 2011;43:27-40
50. Beaulieu C, Busch E, de Crespigny A, et al. Spreading waves of transient and prolonged decreases in water diffusion after subarachnoid hemorrhage in rats. Magn Reson Med 2000;44:110-16 (Pubitemid 30439845)
51. Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med 2011;17:439-47
52. Mies G, Paschen W. Regional changes of blood flow, glucose, and ATP content determined on brain sections during a single passage of spreading depression in rat brain cortex. Exp Neurol 1984;84:249-58 (Pubitemid 14141440)
53. Dreier JP, Korner K, Ebert N, et al. Nitric oxide scavenging by hemoglobin or nitric oxide synthase inhibition by N-nitro-L-arginine induces cortical spreading ischemia when K+ is increased in the subarachnoid space. J Cereb Blood Flow Metab 1998;18:978-90 (Pubitemid 28427865)
54. Petzold GC, Einhaupl KM, Dirnagl U, et al. Ischemia triggered by spreading neuronal activation is induced by endothelin-1 and hemoglobin in the subarachnoid space. Ann Neurol 2003;54:591-8 (Pubitemid 37346065)
55. Bosche B, Graf R, Ernestus RI, et al. Recurrent spreading depolarizations after subarachnoid hemorrhage decreases oxygen availability in human cerebral cortex. Ann Neurol 2010;67:607-17
56. Ostrowski RP, Colohan AR, Zhang JH. Mechanisms of hyperbaric oxygen-induced neuroprotection in a rat model of subarachnoid hemorrhage. J Cereb Blood Flow Metab 2005;25:554-71 (Pubitemid 40562929)
57. Sehba FA, Friedrich V. Early micro vascular changes after subarachnoid hemorrhage. Acta Neurochir Suppl 2011;110:49-55
58. Friedrich V, Flores R, Muller A, et al. Escape of intraluminal platelets into brain parenchyma after subarachnoid hemorrhage. Neuroscience 2010;165:968-75
59. Friedrich V, Flores R, Muller A, et al. Reduction of neutrophil activity decreases early microvascular injury after subarachnoid haemorrhage. J Neuroinflammation 2011;8:103
60. Akopov S, Sercombe R, Seylaz J. Cerebrovascular reactivity: role of endothelium/platelet/leukocyte interactions. Cerebrovasc Brain Metab Rev 1996;8:11-94
61. Yan J, Li L, Khatibi NH, et al. Blood-brain barrier disruption following subarchnoid hemorrhage may be faciliated through PUMA induction of endothelial cell apoptosis from the endoplasmic reticulum. Exp Neurol 2011;230:240-7
62. Feigin VL, Anderson N, Rinkel GJ, et al. Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage. Cochrane Database Syst Rev 2005;CD004583
63. Gomis P, Graftieaux JP, Sercombe R, et al. Randomized, double-blind, placebo-controlled, pilot trial of high-dose methylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg 2010;112:681-8 .
64. Chou SH, Feske SK, Simmons SL, et al. Elevated peripheral neutrophils and matrix metalloproteinase 9 as biomarkers of functional outcome following subarachnoid hemorrhage. Transl Stroke Res 2011;2:600-7
65. Kruyt ND, Biessels GJ, de Haan RJ, et al. Hyperglycemia and clinical outcome in aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke 2009;40:e424-30
66. Schlenk F, Vajkoczy P, Sarrafzadeh A. Inpatient hyperglycemia following aneurysmal subarachnoid hemorrhage: relation to cerebral metabolism and outcome. Neurocrit Care 2009;11:56-63
67. Schmutzhard E, Rabinstein AA. Spontaneous subarachnoid hemorrhage and glucose management. Neurocrit Care 2011;15:281-6
68. Barth M, Capelle HH, Munch E, et al. Effects of the selective endothelin A (ET(lA)) receptor antagonist clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage-preliminary results from a randomized clinical series. Acta Neurochir (Wien) 2007;149:911-18 (Pubitemid 47319143)
69. Gauna C, van den Berghe GH, van der Lely AJ. Pituitary function during severe and life-threatening illnesses. Pituitary 2005;8:213-17
70. Naredi S, Lambert G, Eden E, et al. Increased sympathetic nervous activity in patients with nontraumatic subarachnoid hemorrhage. Stroke 2000;31:901-6 (Pubitemid 30198436)
71. Barth E, Albuszies G, Baumgart K, et al. Glucose metabolism and catecholamines. Crit Care Med 2007;35:S508-18 (Pubitemid 47312187)
72. Seematter G, Binnert C, Martin JL, et al. Relationship between stress, inflammation and metabolism. Curr Opin Clin Nutr Metab Care 2004;7:169-73 (Pubitemid 40340680)
73. Hunt DG, Ivy JL. Epinephrine inhibits insulin-stimulated muscle glucose transport. J Appl Physiol 2002;93(5):1638-43 (Pubitemid 36082974)
74. Hendryk S, Jarzab B, Josko J. Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuro Endocrinol Lett 2004;25:141-7 (Pubitemid 44783371)
75. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8
76. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106:2067-72 (Pubitemid 35192812)
77. Schlenk F, Sarrafzadeh AS. Is continuous insulin treatment safe in aneurysmal subarachnoid hemorrhage? Vasc Health Risk Manag 2008;4:885-91
78. Phillips TJ, Dowling RJ, Yan B, et al. Does treatment of ruptured intracranial aneurysms within 24 hours improve clinical outcome? Stroke 2011;42:1936-45
79. Roos YB, Rinkel GJ, Vermeulen M, et al. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003;CD001245
80. Gaberel T, Magheru C, Emery E, et al. Antifibrinolytic therapy in the management of aneurismal subarachnoid hemorrhage revisited. A meta-analysis. Acta Neurochir (Wien) 2012;154:1-9
81. Muench E, Horn P, Bauhuf C, et al. Effects of hypervolemia and hypertension on regional cerebral blood flow, intracranial pressure, and brain tissue oxygenation after subarachnoid hemorrhage. Crit Care Med 2007;35:1844-51 (Pubitemid 47220357)
82. Le Roux PD. Anemia and transfusion after subarachnoid hemorrhage. Neurocrit Care 2011;15:342-53
83. Dhar R, Zazulia AR, Videen TO, et al. Red blood cell transfusion increases cerebral oxygen delivery in anemic patients with subarachnoid hemorrhage. Stroke 2009;40:3039-44
84. Mutoh T, Ishikawa T, Suzuki A, et al. Continuous cardiac output and near-infrared spectroscopy monitoring to assist in management of symptomatic cerebral vasospasm after subarachnoid hemorrhage. Neurocrit Care 2010;13:331-8
85. Chittiboina P, Conrad S, McCarthy P, et al. The evolving role of hemodilution in treatment of cerebral vasospasm: a historical perspective. World Neurosurg 2011;75:660-4
86. Liu G, Luo J, Zhang L, et al. Meta-analysis of the effectiveness and safety of prophylactic use of nimodipine in patients with an aneurysmal subarachnoid haemorrhage. CNS Neurol Disord Drug Targets 2011;10:834-44
87. Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebocontrolled trial. J Neurosurg 1988;68:505-17
88. Nogueira RG, Lev MH, Roccatagliata L, et al. Intra-arterial nicardipine infusion improves CT perfusion-measured cerebral blood flow in patients with subarachnoid hemorrhage-induced vasospasm. AJNR Am J Neuroradiol 2009;30:160-4
89. Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007;CD000277
90. Barth M, Capelle HH, Weidauer S, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke 2007;38:330-6 (Pubitemid 46188258)
91. Schneider UC, Dreher S, Hoffmann KT, et al. The use of nicardipine prolonged release implants (NPRI) in microsurgical clipping after aneurysmal subarachnoid haemorrhage: comparison with endovascular treatment. Acta Neurochir (Wien) 2011;153:2119-25
92. Kasuya H. Clinical trial of nicardipine prolonged-release implants for preventing cerebral vasospasm: multicenter cooperative study in Tokyo. Acta Neurochir Suppl 2011;110:165-7
93. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011;10:618-25
94. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008;39:3015-21
95. Pradilla G, Garzon-Muvdi T, Ruzevick JJ, et al. Systemic L-citrulline prevents cerebral vasospasm in haptoglobin 2-2 transgenic mice after subarachnoid hemorrhage. Neurosurgery 2012;70:747-56
96. Han BH, Vellimana AK, Zhou ML, et al. Phosphodiesterase 5 inhibition attenuates cerebral vasospasm and improves functional recovery after experimental subarachnoid hemorrhage. Neurosurgery 2012;70:178-86
97. Agrawal A, Patir R, Kato Y, et al. Role of intraventricular sodium nitroprusside in vasospasm secondary to aneurysmal subarachnoid haemorrhage: a 5-year prospective study with review of the literature. Minim Invasive Neurosurg 2009;52:5-8
98. Pluta RM, Oldfield EH, Bakhtian KD, et al. Safety and feasibility of long-term intravenous sodium nitrite infusion in healthy volunteers. PLoS One 2011;6:e14504
99. Asano T, Matsui T. Antioxidant therapy against cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Cell Mol Neurobiol 1999;19:31-44 (Pubitemid 29102092)
100. van den Bergh WM, Algra A, van Kooten F, et al. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 2005;36:1011-15 (Pubitemid 40629294)
101. Schmid-Elsaesser R, Kunz M, Zausinger S, et al. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. Neurosurgery 2006;58:1054-65
102. Chyatte D, Fode NC, Nichols DA, et al. Preliminary report: effects of high dose methylprednisolone on delayed cerebral ischemia in patients at high risk for vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 1987;21:157-60 (Pubitemid 17131115)
103. Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 2005;36:1627-32 (Pubitemid 41098752)
104. Tseng MY, Hutchinson PJ, Turner CL, et al. Biological effects of acute pravastatin treatment in patients after aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled trial. J Neurosurg 2007;107:1092-100 (Pubitemid 350255169)
105. Fei L, Golwa F. Topical application of dexamethasone to prevent cerebral vasospasm after aneurysmal subarachnoid haemorrhage: a pilot study. Clin Drug Investig 2007;27:827-32 (Pubitemid 350145436)
106. Mutoh T, Kobayashi S, Tamakawa N, et al. Multichannel near-infrared spectroscopy as a tool for assisting intra-arterial fasudil therapy for diffuse vasospasm after subarachnoid hemorrhage. Surg Neurol Int 2011;2:68
107. Liu GJ, Wang ZJ, Wang YF, et al. Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Eur J Clin Pharmacol 2012;68:131-9
108. Zhao J, Zhou D, Guo J, et al. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. Neurol Med Chir (Tokyo) 2011;51:679-83
109. Dorhout Mees SM, van den Bergh WM, Algra A, et al. Achieved serum magnesium concentrations and occurrence of delayed cerebral ischaemia and poor outcome in aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2007;78:729-31 (Pubitemid 46998844)
110. Mori K, Yamamoto T, Miyazaki M, et al. Effect of intrathecal magnesium sulfate solution injection via a microcatheter in the cisterna magna on cerebral vasospasm in the canine subarachnoid haemorrhage model. Br J Neurosurg 2012;26:64-8
111. Westermaier T, Stetter C, Vince GH, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med 2010;38:1284-90
112. Prevedello DM, Cordeiro JG, de Morais AL, et al. Magnesium sulfate: role as possible attenuating factor in vasospasm morbidity. Surg Neurol 2006;65(Suppl 1):14-20
113. Stippler M, Crago E, Levy EI, et al. Magnesium infusion for vasospasm prophylaxis after subarachnoid hemorrhage. J Neurosurg 2006;105:723-9 (Pubitemid 44703935)
114. Muroi C, Terzic A, Fortunati M, et al. Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol 2008;69:33-9 (Pubitemid 350181007)
115. Wong GK, Boet R, Poon WS, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage: an updated systemic review and meta-analysis. Crit Care 2011;15:R52
116. Dorhout Mees SM. Magnesium in aneurysmal subarachnoid hemorrhage (MASH II) phase III clinical trial MASH-II study group. Int J Stroke 2008;3:63-5 (Pubitemid 351228147)
117. McGirt MJ, Woodworth GF, Pradilla G, et al. Galbraith award: simvastatin attenuates experimental cerebral vasospasm and ameliorates serum markers of neuronal and endothelial injury in patients after subarachnoid hemorrhage: a dose-response effect dependent on endothelial nitric oxide synthase. Clin Neurosurg 2005;52:371-8
118. Chou SH, Smith EE, Badjatia N, et al. A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage. Stroke 2008;39:2891-3
119. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke 2005; 36:2024-6 (Pubitemid 41266547)
120. Kern M, Lam MM, Knuckey NW, et al. Statins may not protect against vasospasm in subarachnoid haemorrhage. J Clin Neurosci 2009;16:527-30
121. Vergouwen MD, Meijers JC, Geskus RB, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. J Cereb Blood Flow Metab 2009;29:1444-53
122. Vergouwen MD, de Haan RJ, Vermeulen M, et al. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 2010;41:e47-52
123. Tseng MY. Summary of evidence on immediate statins therapy following aneurysmal subarachnoid hemorrhage. Neurocrit Care 2011;15:298-301
124. Sillberg VA, Wells GA, Perry JJ. Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke 2008;39:2622-6
125. Grasso G, Tomasello F. Erythropoietin for subarachnoid hemorrhage: is there a reason for hope? World Neurosurg 2012;77:46-8
126. Springborg JB, Ma X, Rochat P, et al. A single subcutaneous bolus of erythropoietin normalizes cerebral blood flow autoregulation after subarachnoid haemorrhage in rats. Br J Pharmacol 2002;135:823-9 (Pubitemid 34177660)
127. Tseng MY, Hutchinson PJ, Richards HK, et al. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 2009;111:171-80
128. Feiler S, Plesnila N, Thal SC, et al. Contribution of matrix metalloproteinase-9 to cerebral edema and functional outcome following experimental subarachnoid hemorrhage. Cerebrovasc Dis 2011;32:289-95
129. Suzuki H, Hasegawa Y, Ayer R, et al. Effects of recombinant osteopontin on blood-brain barrier disruption after subarachnoid hemorrhage in rats. Acta Neurochir Suppl 2011;111:231-6
130. Duris K, Manaenko A. Suzuki H, et al. {alpha}7 nicotinic acetylcholine receptor agonist PNU-282987 attenuates early brain injury in a perforation model of subarachnoid hemorrhage in rats. Stroke 2011;42:3530-6
131. Sherchan P, Lekic T, Suzuki H, et al. Minocycline improves functional outcomes, memory deficits, and histopathology after endovascular perforation-induced subarachnoid hemorrhage in rats. J Neurotrauma 2011;28:2503-12
132. Ayer R, Jadhav V, Sugawara T, et al. The neuroprotective effects of cyclooxygenase-2 inhibition in a mouse model of aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl 2011;111:145-9
133. Thal SC, Sporer S, Schmid-Elsaesser R, et al. Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome. Crit Care Med 2009;37:2228-34
134. Diringer MN. Management of aneurysmal subarachnoid hemorrhage. Crit Care Med 2009;37:432-40 .
135. Rose FC, Sarner M. Epilepsy after ruptured intracranial aneurysm. Br Med J 1965;1:18-21
136. Sakowitz OW, Raabe A, Vucak D, et al. Contemporary management of aneurysmal subarachnoid hemorrhage in germany: results of a survey among 100 neurosurgical departments. Neurosurgery 2006;58:137-45
137. Lanzino G, D'Urso PI, Suarez J. Seizures and anticonvulsants after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2011;15:247-56
138. Butzkueven H, Evans AH, Pitman A, et al. Onset seizures independently predict poor outcome after subarachnoid hemorrhage. Neurology 2000;55:1315-20
139. Hart RG, Byer JA, Slaughter JR, et al. Occurrence and implications of seizures in subarachnoid hemorrhage due to ruptured intracranial aneurysms. Neurosurgery 1981;8:417-21 (Pubitemid 11104838)
140. Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005;36:583-7 (Pubitemid 40352567)
141. Pinto AN, Canhao P, Ferro JM. Seizures at the onset of subarachnoid haemorrhage. J Neurol 1996;243:161-4 (Pubitemid 26026653)
142. Rosengart AJ, Huo JD, Tolentino J, et al. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg 2007;107:253-60 (Pubitemid 47219366)
143. Zubkov AY, Wijdicks EF. Antiepileptic drugs in aneurysmal subarachnoid hemorrhage. Rev Neurol Dis 2008;5:178-81
144. Chumnanvej S, Dunn IF, Kim DH. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery 2007;60:99-102 (Pubitemid 46102931)
145. Dorhout Mees SM, van den Bergh WM, Algra A, et al. Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007;CD006184
146. McGirt MJ, Woodworth GF, Ali M, et al. Persistent perioperative hyperglycemia as an independent predictor of poor outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg 2007;107:1080-5 (Pubitemid 350258453)
147. Kruyt ND, Biessels GJ, DeVries JH, et al. Hyperglycemia in aneurysmal subarachnoid hemorrhage: a potentially modifiable risk factor for poor outcome. J Cereb Blood Flow Metab 2010;30:1577-87
148. Van den Berghe G, Schoonheydt K, Becx P, et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005;64:1348-53 (Pubitemid 40570499)
149. Bell DA, Strong AJ. Glucose/insulin infusions in the treatment of subarachnoid haemorrhage: a feasibility study. Br J Neurosurg 2005;19:21-4 (Pubitemid 40824368)
150. Kanamaru K, Weir BK, Simpson I, et al. Effect of 21-aminosteroid U-74006F on lipid peroxidation in subarachnoid clot. J Neurosurg 1991;74:454-9
151. Steinke DE, Weir BK, Findlay JM, et al. A trial of the 21-aminosteroid U74006F in a primate model of chronic cerebral vasospasm. Neurosurgery 1989;24:179-86 (Pubitemid 19044581)
152. Zuccarello M, Marsch JT, Schmitt G, et al. Effect of the 21-aminosteroid U-74006F on cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg 1989;71:98-104 (Pubitemid 19196559)
153. Zhang S, Wang L, Liu M, et al. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2010;CD006778
154. Jang YG, Ilodigwe D, Macdonald RL. Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care 2009;10:141-7
155. Claassen J, Carhuapoma JR, Kreiter KT, et al. Global cerebral edema after subarachnoid hemorrhage: frequency, predictors, and impact on outcome. Stroke 2002;33:1225-32 (Pubitemid 34520392)
156. Thal SC, Sporer S, Klopotowski M, et al. Brain edema formation and neurological impairment after subarachnoid hemorrhage in rats. J Neurosurg 2009;111:988-94